Lubbock TX 伯基特淋巴瘤临床试验
3项针对 伯基特淋巴瘤的研究正在 Lubbock及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Covenant Children's Hospital, Lubbock
- UMC Cancer Center / UMC Health System, Lubbock
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Covenant Children's Hospital, Lubbock
- UMC Cancer Center / UMC Health System, Lubbock
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Covenant Children's Hospital, Lubbock
- UMC Cancer Center / UMC Health System, Lubbock
其他城市的 伯基特淋巴瘤试验
- Houston, TX21 项研究
- Milwaukee, WI16 项研究
- Philadelphia, PA16 项研究
- New York City, NY14 项研究
- Chicago, IL13 项研究
- Cincinnati, OH12 项研究
- Seattle, WA12 项研究
- Atlanta, GA11 项研究
- Boston, MA10 项研究
- Los Angeles, CA10 项研究
- Durham, NC10 项研究
- Aurora, CO10 项研究
Lubbock的其他研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。